Bet on three Merrimack assets, Ipsen takes others for $1B+
In a potential $1 billion-plus deal that Cowen and Co. analyst Eric Schmidt described as "a necessary and favorable solution" for Merrimack Pharmaceuticals Inc.'s financial straits, the company is selling its approved pancreatic cancer drug Onivyde and its generic version of Doxil to Ipsen SA.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST